Total Payments
$22,527
2024 Payments
$1,202
Companies
61
Transactions
798
Medicare Patients
11,874
Medicare Billing
$1.6M
Payment Breakdown by Category
Food & Beverage$13,592 (60.3%)
Research$8,401 (37.3%)
Education$534.21 (2.4%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $13,592 | 767 | 60.3% |
| Unspecified | $8,401 | 3 | 37.3% |
| Education | $534.21 | 28 | 2.4% |
Payments by Type
General
$14,126
795 transactions
Research
$8,401
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $8,567 | 7 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $1,780 | 118 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,356 | 46 | $0 (2024) |
| Amgen Inc. | $947.74 | 39 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $835.10 | 65 | $0 (2024) |
| Merck Sharp & Dohme LLC | $691.69 | 45 | $0 (2024) |
| Genentech USA, Inc. | $668.98 | 40 | $0 (2022) |
| PFIZER INC. | $597.28 | 99 | $0 (2020) |
| Incyte Corporation | $583.68 | 25 | $0 (2024) |
| Janssen Biotech, Inc. | $520.48 | 30 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,202 | 39 | AstraZeneca Pharmaceuticals LP ($345.52) |
| 2023 | $1,027 | 36 | E.R. Squibb & Sons, L.L.C. ($224.87) |
| 2022 | $643.74 | 23 | Novartis Pharmaceuticals Corporation ($222.62) |
| 2021 | $181.22 | 9 | Lilly USA, LLC ($71.20) |
| 2020 | $540.48 | 26 | Agios Pharmaceuticals, Inc. ($121.66) |
| 2019 | $10,580 | 280 | Takeda Pharmaceuticals U.S.A., Inc. ($6,192) |
| 2018 | $5,183 | 189 | Takeda Pharmaceuticals U.S.A., Inc. ($2,374) |
| 2017 | $3,169 | 196 | Novartis Pharmaceuticals Corporation ($384.70) |
All Payment Transactions
798 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $13.29 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $28.48 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Education | In-kind items and services | $17.02 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: Oncology | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $21.87 | General |
| 10/18/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $27.41 | General |
| Category: Oncology | ||||||
| 10/11/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $27.49 | General |
| Category: Oncology | ||||||
| 10/09/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $124.99 | General |
| 10/03/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: Oncology | ||||||
| 09/27/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 09/26/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $23.87 | General |
| Category: Immunology | ||||||
| 08/29/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $28.54 | General |
| Category: Oncology | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $21.72 | General |
| Category: Oncology | ||||||
| 08/01/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $14.43 | General |
| 07/18/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $28.19 | General |
| Category: Oncology | ||||||
| 07/11/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Oncology | ||||||
| 07/02/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Education | In-kind items and services | $30.00 | General |
| Category: Rare Disease | ||||||
| 06/27/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $23.15 | General |
| 06/20/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $19.06 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2024 | Bayer Healthcare Pharmaceuticals Inc. | Vitrakvi (Drug), Stivarga | Food and Beverage | In-kind items and services | $12.33 | General |
| Category: Oncology | ||||||
| 06/06/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.15 | General |
| Category: Hematology/Oncology | ||||||
| 05/30/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma | Takeda Pharmaceuticals U.S.A., Inc. | $8,401 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 50 | 2,728 | 54,279 | $2.1M | $317,801 |
| 2022 | 52 | 3,324 | 66,313 | $2.2M | $338,895 |
| 2021 | 52 | 2,754 | 63,689 | $2.1M | $369,840 |
| 2020 | 55 | 3,068 | 112,047 | $2.9M | $528,816 |
Total Patients
11,874
Total Services
296,328
Medicare Billing
$1.6M
Procedure Codes
209
All Medicare Procedures & Services
209 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 265 | 768 | $282,624 | $69,604 | 24.6% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 16 | 22,345 | $446,900 | $52,492 | 11.7% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 18 | 20 | $96,040 | $22,184 | 23.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 34 | 231 | $82,467 | $20,950 | 25.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 50 | 199 | $140,693 | $19,267 | 13.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 155 | 229 | $57,250 | $13,165 | 23.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 49 | 95 | $47,120 | $12,254 | 26.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 288 | 984 | $62,976 | $10,176 | 16.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 288 | 1,007 | $20,140 | $8,459 | 42.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 58 | 58 | $32,770 | $6,932 | 21.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 276 | 896 | $32,256 | $6,812 | 21.1% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 12 | 1,645 | $190,820 | $6,329 | 3.3% |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 2023 | 15 | 23 | $63,526 | $6,247 | 9.8% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 28 | 31 | $33,077 | $5,287 | 16.0% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 15 | 11,730 | $58,650 | $4,723 | 8.1% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 21 | 78 | $16,458 | $4,226 | 25.7% |
| 83521 | Measurement of immunoglobulin light chains | Office | 2023 | 53 | 242 | $14,520 | $4,096 | 28.2% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 36 | 175 | $27,475 | $3,719 | 13.5% |
| G6013 | Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | Office | 2023 | 15 | 21 | $14,700 | $3,557 | 24.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 35 | 72 | $22,536 | $3,396 | 15.1% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 17 | 62 | $21,328 | $2,961 | 13.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 40 | $9,880 | $2,422 | 24.5% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 73 | 172 | $10,320 | $2,298 | 22.3% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 20 | 22 | $14,454 | $1,985 | 13.7% |
| 82378 | Carcinoembryonic antigen (cea) protein level | Office | 2023 | 24 | 106 | $10,494 | $1,969 | 18.8% |
About Dr. David Friedman, MD
Dr. David Friedman, MD is a Hematology & Oncology healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477526895.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Friedman, MD has received a total of $22,527 in payments from pharmaceutical and medical device companies, with $1,202 received in 2024. These payments were reported across 798 transactions from 61 companies. The most common payment nature is "Food and Beverage" ($13,592).
As a Medicare-enrolled provider, Friedman has provided services to 11,874 Medicare beneficiaries, totaling 296,328 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 209 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology
- Location San Antonio, TX
- Active Since 02/08/2006
- Last Updated 04/22/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1477526895
Products in Payments
- Ninlaro (Drug) $8,401
- OPDIVO (Biological) $598.86
- KEYTRUDA (Biological) $546.48
- XARELTO (Drug) $494.78
- Venclexta (Drug) $433.31
- JAKAFI (Drug) $423.74
- CALQUENCE (Drug) $380.16
- PROMACTA (Drug) $371.61
- KISQALI (Drug) $333.13
- TECENTRIQ (Biological) $291.23
- Kyprolis (Biological) $280.05
- ADCETRIS (Biological) $279.47
- TASIGNA (Drug) $224.88
- Lonsurf (Drug) $219.38
- CYRAMZA (Drug) $211.80
- ZEJULA (Drug) $210.88
- XTANDI (Drug) $196.55
- SCEMBLIX (Drug) $192.52
- Cabometyx (Drug) $189.10
- DARZALEX (Biological) $178.76
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in San Antonio
Dr. Timothy Fenske, Md, MD
Hematology & Oncology — Payments: $770,308
Hematology & Oncology $770,308
Dr. Paul Shaughnessy, M.d, M.D
Hematology & Oncology — Payments: $522,755
Hematology & Oncology $522,755
Francis Giles, M.d, M.D
Hematology & Oncology — Payments: $519,610
Hematology & Oncology $519,610
Dr. John Renshaw, M.d, M.D
Hematology & Oncology — Payments: $322,856
Hematology & Oncology $322,856
Dr. Elizabeth Bowhay-Carnes, M.d, M.D
Hematology & Oncology — Payments: $200,175
Hematology & Oncology $200,175
Dr. Marcela Mazo Canola, M.d, M.D
Hematology & Oncology — Payments: $150,233
Hematology & Oncology $150,233